文献速递肝胆胰外科围术期管理与 ERAS

机器人与腹腔镜肾上腺切除术围手术期结局:大型国际多中心经验

Perioperative outcomes of robotic and laparoscopic adrenalectomy: a large international multicenter experience.
PubMed 文献 · Surg Endosc · 2020-04-23

该回顾性多中心研究纳入477例行肾上腺切除术的患者,比较机器人与腹腔镜手术的围手术期结局。结果显示两组术中及术后并发症率相近,肿瘤大小是总体并发症的唯一独立预测因素,微创手术对≥6 cm的肾上腺肿瘤仍可行。

要点

  • 机器人与腹腔镜肾上腺切除术的术中并发症率分别为6.3%和6%,术后并发症率分别为5.4%和3.5%。
  • 机器人组肿瘤尺寸(中位4 cm)显著大于腹腔镜组(中位3 cm),但并发症率无显著差异。
  • 肿瘤大小是总体并发症的唯一独立预测因素(OR 1.287;CI 1.128-1.468;p < 0.001)。

核心结论

  • 肾上腺肿瘤可安全地通过机器人或腹腔镜策略治疗。
  • 微创手术对于较大的肾上腺肿块(≥6 cm)似乎也是可行的。
  • 肿瘤大小是总体并发症的唯一预测因素。

研究设计与样本

  • 回顾性多中心研究,纳入2008年3月至2018年2月在两所三级转诊中心由六位经验丰富的外科医生连续治疗的477例肾上腺切除术患者。
  • 排除43例因肿瘤或麻醉禁忌而开放手术的患者。
  • 机器人组110例,腹腔镜组367例。

主要发现

  • 机器人组与腹腔镜组术中并发症率分别为6.3%和6%。
  • 机器人组术后并发症率为5.4%,腹腔镜组为3.5%。
  • 机器人组肿瘤大小中位4 cm(IQR 2.6-6 cm),显著大于腹腔镜组中位3 cm(IQR 2.3-4.1 cm)(p = 0.01)。
  • 多变量分析显示肿瘤大小是总体并发症的唯一独立预测因素(OR 1.287;CI 1.128-1.468;p < 0.001)。

临床怎么用

  • 对于肾上腺肿瘤,机器人或腹腔镜微创手术均可安全实施。
  • 对于≥6 cm的肾上腺肿瘤,微创手术仍可考虑,但需注意并发症风险随肿瘤增大而增加。
  • 肿瘤大小是术前评估并发症风险的重要指标。

局限性

  • 回顾性研究设计。
  • 两组ASA评分存在差异(机器人组中位3,腹腔镜组中位2,p = 0.03)。
  • 机器人组肿瘤尺寸显著大于腹腔镜组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the study was to describe the surgical outcomes of a retrospective series of consecutive patients treated with laparoscopic and robotic approach for adrenal masses in two tertiary referral centers. METHODS: We retrospectively gathered data of 477 patients submitted to adrenalectomy performed at two Institutions from March 2008 to February 2018 by six highly experienced surgeons. We excluded from the analysis 43 patients that had an open approach for tumors or for anesthetic contraindications to minimally invasive surgery (MIS). Patients were selected for surgery after a radiologic and an endocrinology work up. Preoperative, perioperative and postoperative data were recorded. RESULTS: Overall, 477 patients were included in the study. The robotic and the laparoscopic group included 110 and 367 patients, respectively. The preoperative characteristics were similar in both groups except for ASA score with a median (IQR) of 3 and 2 in the robotic and in the laparoscopic group, respectively (p = 0.03). Tumor size of adrenal tumors treated robotically (4, IQR 2.6-6 cm) was significantly larger than those treated laparoscopically (3, IQR 2.3-4.1 cm) (p = 0.01). The intraoperative complication rates were similar between robotic and laparoscopic groups (6.3% and 6%, respectively). The postoperative complication rate was 5.4% for robotic group and similarly 3.5% for laparoscopic adrenalectomy strategy. We analyzed the tumor ≥ 6 cm, with 29 patients in the robotic group and 43 in the laparoscopic one, with an overall complication rate of 19.5%. At multivariable analyses tumor size (OR 1.287; CI 1.128-1.468; p < 0.001) was the only independent predictor of overall complication. CONCLUSION: Adrenal tumors can be safely treated either by robotic or laparoscopic strategy. MIS seems to be feasible also in larger adrenal masses (≥ 6 cm). Tumor size represents the only predictive factors for overall complication.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Sforza S, Minervini A, Tellini R, et al. Perioperative outcomes of robotic and laparoscopic adrenalectomy: a large international multicenter experience. Surg Endosc. 2020. PMID: 32328826. doi:10.1007/s00464-020-07578-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。